Q32 Bio (NASDAQ:QTTB – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Valuation & Earnings
This table compares Q32 Bio and Roivant Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Q32 Bio | $53.74 million | 4.75 | $29.82 million | $2.66 | 5.66 |
| Roivant Sciences | $8.26 million | 3,005.09 | -$299.77 million | ($0.60) | -57.52 |
Insider & Institutional Ownership
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Q32 Bio and Roivant Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Q32 Bio | N/A | 149.23% | 34.50% |
| Roivant Sciences | -3,629.19% | -20.54% | -19.43% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Q32 Bio and Roivant Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Q32 Bio | 0 | 2 | 4 | 0 | 2.67 |
| Roivant Sciences | 1 | 1 | 10 | 0 | 2.75 |
Q32 Bio presently has a consensus target price of $22.33, suggesting a potential upside of 48.39%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Given Q32 Bio’s higher possible upside, research analysts clearly believe Q32 Bio is more favorable than Roivant Sciences.
Volatility and Risk
Q32 Bio has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Summary
Q32 Bio beats Roivant Sciences on 9 of the 14 factors compared between the two stocks.
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.
